Amyotrophic Lateral Sclerosis Treatment Market to Reach USD 1.21 Billion by 2030 Driven by Gene Therapy Approvals and Expanding Drug Pipeline

Mordor Intelligence has published a new report on the Amyotrophic Lateral Sclerosis Treatment Market, offering a comprehensive analysis of trends, growth drivers, and future projections.

The global amyotrophic lateral sclerosis (ALS) treatment market is poised for steady growth. Valued at approximately USD 0.9 billion in 2025, the market is expected to increase to USD 1.21 billion by 2030, reflecting a 5.94% CAGR from 2025 through 2030. The landscape is shifting from symptomatic relief to targeted therapies, including gene-based and antisense oligonucleotide (ASO) treatments. Recent approvals, regulatory incentives, and manufacturing scale-up are shaping how treatment access and costs evolve over the forecast period.

Report Overview: https://www.mordorintelligence.com/industry-reports/amyotrophic-lateral-sclerosis-treatment-market?utm_source=openpr

Key Trends

Approved Gene‐Targeting Therapy: The first ASO therapy for SOD1-linked ALS was approved in the United States in 2023 and in Europe in 2024. This milestone marks a shift toward treatments that slow disease progression rather than only managing symptoms.

Expanding Orphan‐Drug Pipeline: Multiple companies are pursuing drug targets beyond riluzole and edaravone, benefiting from orphan-drug designations and waived regulatory fees. These measures are accelerating time-to-market and patient access.

Manufacturing Capacity Growth: Investment in oligonucleotide manufacturing and scalable viral vector platforms is underway. This is reducing per-dose costs and improving margins for gene-based products.

Regional Leadership: North America remains the largest regional market, supported by strong healthcare infrastructure, reimbursement policies, and high disease prevalence. Asia‐Pacific is expected to grow fastest, driven by rising awareness, expanding clinical trials, and investment in ALS care.

Market Segmentation

The ALS treatment market includes various treatment types, drug classes, and administration routes. Highlights include:

By Treatment Type

Medication

Stem Cell Therapy

Gene / ASO Therapy

Others

By Drug Class

Riluzole

Edaravone

Antisense Oligonucleotides

Combination / Multi-target

Symptomatic Modifiers

By Route of Administration

Oral

Intravenous

Intrathecal

Sub-cutaneous

By End-user

Hospitals

Specialty Clinics / ALS Centers

Home-care Settings

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography:

North America

Europe

Asia‐Pacific

South America

Middle East & Africa

Explore Our Full Library of Healthcare Industry Research Reports

https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=openpr

Key Players

Several firms lead this moderately concentrated market, focusing on drug approvals, pipeline development, and geographic expansion. Notable companies include:

Mitsubishi Tanabe Pharma - Developer of edaravone, and key player in gene therapy efforts.

CORESTEM Inc. - Engaged in cell-based and gene therapy research targeting neuromuscular disorders.

BrainStorm Cell Therapeutics - Focused on stem cell and regenerative approaches in ALS.

Amylyx Pharmaceuticals - Developed sodium phenylbutyrate/taurursodiol (Relyvrio), though it was withdrawn in 2024 following late-stage trial failure

Biogen, along with Ionis Pharmaceuticals - Co-developers of tofersen (Qalsody), the ASO treatment for SOD1-ALS approved in the U.S. in 2023 and Europe in 2024

For More information visit: https://www.mordorintelligence.com/industry-reports/amyotrophic-lateral-sclerosis-treatment-market/companies?utm_source=openpr

Conclusion

The ALS treatment market is on a steady growth path toward USD 1.21 billion by 2030, driven by approval of disease-modifying therapies and expanding research into novel treatment options. While medications like riluzole still dominate, gene and ASO therapies are gaining momentum. Manufacturing investments and regulatory support are lowering costs and shortening timelines. As North America remains the largest region and Asia-Pacific rises rapidly, patient access and treatment effectiveness are expected to improve. Continued focus on pipeline development and broader therapy portfolios will support future market expansion.

Industry Related Reports

Rare Neurological Disease Treatment Market: The report covers Rare Neurological Disorders Market Trends and the market is segmented by Segmented by Drug Type (Biologics and Small Molecules), Mode of Administration (Intravenous and Oral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Get More Insights: https://www.mordorintelligence.com/industry-reports/rare-neurological-disease-treatment-market?utm_source=openpr

Neurodegenerative Disease Market: The Neurodegenerative Disease Market report segments the industry into By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types), By Drug Type (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Other Drug Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

Get More Insights: https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market?utm_source=openpr

Neuroprotective Agents Market: The Neuroprotective Agents Market report segments the industry into By Drug Class (Anesthetics, Antagonists, Antidepressants, Cytokines, Others), By Application (Alzheimer's Disease, Dementia, Epilepsy, Multiple Sclerosis, Others), By Route of Administration (Oral, Topical, Epidural, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and more), and Geography.

Get More Insights: https://www.mordorintelligence.com/industry-reports/global-neuroprotective-agents-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.